Clinical trials · source year
8 selected, source-linked clinical trial records dated 2009. This is selective source coverage, not a complete timeline.
8 selected records.
6 connected profiles.
8 distinct public records.
Cited chronology
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00063310 at 2026-07-30T22:26:45.017Z. Its registry update date was 2009-12-11, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00414973 at 2026-07-30T22:26:45.016Z. Its registry update date was 2009-10-28, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Afamelanotide
PeptideScanner retained ClinicalTrials.gov record NCT00859534 at 2026-07-30T22:26:45.018Z. Its registry update date was 2009-09-15, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT00974272 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-09-10, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT00434772 at 2026-07-30T22:26:45.006Z. Its registry update date was 2009-05-28, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT00817271 at 2026-07-30T22:26:45.011Z. Its registry update date was 2009-05-07, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00051558 at 2026-07-30T22:26:45.005Z. Its registry update date was 2009-03-12, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Lanreotide
PeptideScanner retained ClinicalTrials.gov record NCT00565097 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-02-17, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗